Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. (Q37486753)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

review article

1 reference

title

Current status of cediranib: the rapid development of a novel anti-angiogenic therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

main subject

angiogenesis inhibitor

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Colin R Lindsay

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Jim Cassidy

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

1 May 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

421-432

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

28 January 2020

cites work

1 reference

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases

21 January 2018

1 reference

Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants

21 January 2018

1 reference

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

21 January 2018

1 reference

Vascular endothelial growth factor as a target for anticancer therapy

21 January 2018

1 reference

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

21 January 2018

1 reference

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

21 January 2018

1 reference

Fibroblast growth factor signaling in tumorigenesis

21 January 2018

1 reference

Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.

21 January 2018

1 reference

AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor

21 January 2018

1 reference

Lymphangiogenesis and cancer metastasis

21 January 2018

1 reference

Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer

21 January 2018

1 reference

Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition

21 January 2018

1 reference

Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer

21 January 2018

1 reference

Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts

21 January 2018

1 reference

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

21 January 2018

1 reference

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

A physiologic imaging pilot study of breast cancer treated with AZD2171.

21 January 2018

1 reference

A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer

21 January 2018

1 reference

Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast canc

21 January 2018

1 reference

Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).

21 January 2018

1 reference

Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy

21 January 2018

1 reference

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19450171%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference